Eli Lilly and Company $LLY Shares Sold by Artemis Investment Management LLP

Artemis Investment Management LLP decreased its stake in Eli Lilly and Company (NYSE:LLY) by 20.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 76,310 shares of the company’s stock after selling 19,638 shares during the period. Artemis Investment Management LLP’s holdings in Eli Lilly and Company were worth $88,297,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. BlackRock Inc. boosted its stake in shares of Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after purchasing an additional 1,046,558 shares in the last quarter. State Street Corp raised its holdings in Eli Lilly and Company by 1.7% in the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after buying an additional 605,752 shares during the last quarter. Bank of America Corp DE acquired a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Eli Lilly and Company by 1.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock worth $8,647,153,000 after acquiring an additional 137,364 shares during the last quarter. Finally, Jennison Associates LLC lifted its holdings in shares of Eli Lilly and Company by 7.9% during the second quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock worth $6,550,587,000 after purchasing an additional 400,538 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of LLY traded down $39.79 during mid-day trading on Thursday, reaching $1,148.93. 1,507,727 shares of the stock traded hands, compared to its average volume of 2,966,079. The firm has a fifty day moving average price of $1,173.51 and a 200 day moving average price of $1,094.59. Eli Lilly and Company has a 1 year low of $783.85 and a 1 year high of $1,292.65. The company has a market cap of $1.08 trillion, a price-to-earnings ratio of 38.63, a price-to-earnings-growth ratio of 1.42 and a beta of 0.46. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. During the same quarter in the previous year, the company earned $6.31 EPS. The business’s quarterly revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities research analysts predict that Eli Lilly and Company will post 36.66 earnings per share for the current year.

Analyst Ratings Changes

LLY has been the subject of several recent analyst reports. UBS Group set a $1,376.00 price objective on shares of Eli Lilly and Company in a research report on Friday, August 7th. HSBC boosted their target price on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a report on Thursday, September 10th. Leerink Partners increased their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a report on Thursday, June 25th. Berenberg Bank set a $1,400.00 price objective on Eli Lilly and Company and gave the company a “buy” rating in a research note on Tuesday, September 15th. Finally, Sanford C. Bernstein upped their target price on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research report on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $1,313.43.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analyst raises price target: Cantor Fitzgerald lifted its LLY price target to $1,440 from $1,410 and maintained an “overweight” rating, signaling confidence in Lilly’s long-term earnings outlook. Benzinga coverage
• Positive Sentiment: Technical momentum improves: LLY recently moved above its 50-day moving average, a technical signal that may attract short-term buyers and suggests improving near-term momentum. Eli Lilly overtakes 50-day moving average
• Positive Sentiment: Pipeline supports the long-term case: Investors continue to highlight strong GLP-1 demand, oncology growth and next-generation obesity candidate retatrutide. Retatrutide’s potential efficacy and a possible FDA filing in 2027 could provide another major growth catalyst. Three bargains outside AI
• Neutral Sentiment: Oncology remains a developing growth driver: Jaypirca, Inluriyo and Retevmo could help offset slower Verzenio sales and declines from mature products, although the financial impact will depend on commercial execution and upcoming results. Eli Lilly oncology portfolio ahead of earnings
• Negative Sentiment: Valuation and competition remain overhangs: Analysts note that LLY trades at a demanding multiple, while increasing competition in the GLP-1 market and potential pricing pressure could limit the pace of future earnings growth. New WHO childhood-obesity guidance may also create uncertainty around the market’s long-term expansion. Is the LLY dip a buying opportunity?

Insider Activity

In related news, CAO Donald A. Zakrowski sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 13,500 shares of company stock valued at $15,958,170. Insiders own 0.14% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.